Search - tctmd.com

Displaying 161 - 173 of 173

Sort: Relevancy | Date

News Conference News ESC 2016

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Michael O'Riordan

August 30, 2016

News Daily News

Interactive Smartphone App Can Motivate MI Patients to Take Their Meds

Caitlin E. Cox

June 06, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2016

Shelley Wood

February 01, 2016

News Daily News

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Michael O'Riordan

January 26, 2016

News Daily News

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Michael O'Riordan

December 15, 2015

News Industry News

Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled

November 23, 2015

News Conference News AHA 2015

Knowing Genetic Risk for MI Motivates Patients, Physicians to Get Cholesterol Levels Lower

Yael L. Maxwell

November 08, 2015

News Industry News

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

August 20, 2015

News Daily News

Diabetes Often Goes Unrecognized in Patients Hospitalized With Acute MI

May 07, 2015

News Conference News ESC 2014

IBIS-4: High-Dose Statin Therapy May Reverse Atherosclerosis in STEMI

Todd Neale

September 02, 2014

News Daily News

Diabetes Drug Aleglitazar Fails to Reduce Ischemic Outcomes in Diabetics with Recent ACS

L.A. McKeown

April 11, 2014

News Daily News

High-Risk Subgroups Derive Kidney Protection from Rosuvastatin

Caitlin E. Cox

October 11, 2013

News Daily News

Calcium Scanning May Lower CAD Risk at No Extra Cost

March 23, 2011

Advertisement

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Interactive Smartphone App Can Motivate MI Patients to Take Their Meds

TCTMD’s Top 10 Most Popular Stories for January 2016

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled

Knowing Genetic Risk for MI Motivates Patients, Physicians to Get Cholesterol Levels Lower

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

Diabetes Often Goes Unrecognized in Patients Hospitalized With Acute MI

IBIS-4: High-Dose Statin Therapy May Reverse Atherosclerosis in STEMI

Diabetes Drug Aleglitazar Fails to Reduce Ischemic Outcomes in Diabetics with Recent ACS

High-Risk Subgroups Derive Kidney Protection from Rosuvastatin

Calcium Scanning May Lower CAD Risk at No Extra Cost

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content